Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

point and represent results from Period 1 of a 2-period study from the initial open-label portion of the PRESERVE trial examining patients with moderately active rheumatoid arthritis. The results demonstrated that treatment with ENBREL added to MTX reduced radiographic progression in 82 percent (modified Total Sharp Score [mTSS] change less than or equal to 0.5) of these patients, all of whom had an inadequate response to MTX alone.  Results also showed that 86 percent of patients achieved Disease Activity Score (DAS) 28 low disease activity and 67 percent achieved DAS28 clinical remission with continuous treatment with ENBREL plus MTX.

Improvement in Patient-Reported Outcomes with Etanercept-Methotrexate (MTX) Therapy in Moderately Active Rheumatoid Arthritis: Interim Results of the PRESERVE Trial Patients with RA often experience impairment in physical function, health-related quality of life (HR-QOL) and productivity at work. Patient-reported outcomes from the initial open-label portion of the PRESERVE trial examining patients with moderate rheumatoid arthritis showed clinically important improvements in measures of physical function, disease activity, pain, fatigue, HR-QOL and work productivity after 36 weeks of ENBREL added to MTX.

Ankylosing SpondylitisAssociation Between Nocturnal Back Pain and Fatigue in Ankylosing Spondylitis and Improvements in Both Patient-Reported Outcomes with Etanercept Therapy Nocturnal back pain in AS patients is a strong predictor of fatigue. In an exploratory pooled analysis, data combined from four clinical trials of AS patients were analyzed and found that nocturnal back pain was a significant predictor of fatigue and showed that ENBREL provided reductions in nocturnal back pain and fatigue.  

Psoriatic ArthritisPsoriasis Patients with Psoriatic Arthritis and Axial Involvement Have a Higher Disease Burden than Those without Axial Involvement but Similar Treatment Outcomes: Results from PR
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... Silver Creek Pharmaceuticals, Inc. announced today the ... from the National Institute of Health (NIH). ... based biotechnology company that discovers and develops ... disease. This award will be used to advance their ... a heart attack. Silver Creek,s Smart Growth ...
(Date:5/5/2015)... 2015  Trovagene, Inc. (NASDAQ:  TROV), a developer ... results for the three months ended March 31, ... we presented favorable clinical results at ASCO GI, ... our Precision Cancer Monitoring platform,s ability to detect ... lung cancers," said Antonius Schuh, Ph.D., chief executive ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... MORGANTOWN, W.Va., Jan. 11, 2011 A Blanchette ... the Journal of Neuroscience reveals underlying causes for ... identifies promising pharmaceutical solutions for the devastating condition ... the United States. The BRNI study is the ...
... Jan. 11, 2011 Hill-Rom Holdings, Inc. (NYSE: ... on Wednesday, January 26, 2011.  The company will host a ... 8 a.m. EST. Earnings Release:   Hill-Rom,s ... December 31, 2010, will be issued to the public after ...
Cached Medicine Technology:The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 2The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 3Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2
(Date:5/6/2015)... In celebration of their twentieth anniversary, ... they will give away a deluxe human hair lace wig ... steps to enter on a third-party giveaway tool. The important ... can be the winner. , The hair is a crown, ... destination for such a jewel for the past 20 years. ...
(Date:5/6/2015)... 06, 2015 Qualidigm , ... has hired healthcare executive Ann Olson, RN, BSN, ... will lead Qualidigm’s growing home healthcare services and ... improve the quality, safety, and cost-effectiveness of healthcare ... from Interim HealthCare of North Haven, Inc., a ...
(Date:5/6/2015)... Pass, OR (PRWEB) May 06, 2015 ... for maintaining eye health as we age, is fully ... the Sharon Kleyne Hour™ Power of Water® radio show. ... the need to drink sufficient water each day. As ... Nature’s Tears® EyeMist® for dry eye, Kleyne has extensive ...
(Date:5/6/2015)... 2015 Chinese technology company, Elink-IOT, has ... to raise AUD$150,000 to finalize development of Watcher, the ... smart watch designed to help the owner keep track ... when the item is out of range. , ... the wearer and sends alerts on its E-paper display, ...
(Date:5/6/2015)... LINET Americas has been awarded the ... small business category. The award was given for outstanding ... is given on an annual basis to foreign owned ... to philanthropy. Since 1998, the Charlotte International Cabinet ... Mayor’s International Community Awards. The award was presented to ...
Breaking Medicine News(10 mins):Health News:PremierLaceWigs.com Human Hair Lace Wigs Giveaway Could Change Your Hairstyle 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 3Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 3Health News:Crowdfunding campaign Launched for World’s First Anti-Loss Smart Watch 2Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2
... Dec. 10 N3 Oceanic, Inc. announced the addition of ... developed by cardiologist Dr. Jeffrey Shapiro, MD, Assistant Professor of ... and NYU Langone Medical Center, who has been giving the ... life-changing results. Dr. Shapiro states, Orosine is the most significant ...
... Global Med Technologies(R), Inc.,("Global Med" or the "Company") ... technology company, today announced that due to,inquiries from ... that was,received from Victory Park Capital Advisors, LLC ... Global Med,s Board of Directors to investigate various,business ...
... Botanical Council (ABC) has officially launched its Adopt-an-Herb program, ... ( Camellia sinensis ). For the next three years, ... ensure that abstracts (summaries) of the latest published scientific ... ABC,s HerbMedPro database, one of the most robust and ...
... Dec. 10 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... ("OTC") pharmaceuticals and personal care products company,announced today its ... growth without considering acquisitions in the range of 21% ... the range of 27% - 28%. These estimates,are ...
... stress of the economy,have you pulling your hair out? ... Now is the time to take a breather, rejuvenate, ... emotionally,physically and financially, which is why many spas are offering ... get the other half off,there is something for everyone. ...
... Dec. 10 Napo Pharmaceuticals, Inc. ("Napo"),is pleased ... for the license of crofelemer for all indications ... Japan, and certain,indications worldwide. Crofelemer is Napo,s ... 3 trial for the treatment of,chronic diarrhea in ...
Cached Medicine News:Health News:Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the 'Ultimate Cardio Protection' Against Heart Attacks, Strokes and Heart Failure. 2Health News:Global Med Technologies(R), Inc. Clarifies Proposal Received from Victory Park Capital Advisors, LLC 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 3Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 4Health News:Genomma Lab Announces 2009 Earnings Guidance 2Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 2Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 3Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 4Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 5
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... an "assembly-line worker" for routine staining protocols ... Programmable continuous slide stainer for routine stains. ... in short time. Its large number of ... working principle provides a high throughput. A ...
Cholesterol, Total. An automated analyzer test kits....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
Medicine Products: